Immudyne manufactures, distributes and sells natural immune support products containing yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through testing and analysis to support the immune system. The Company's products include once a day oral intake tablets and topical creams and gels for skin application.

TypePublic
HQMount Kisco, US
Founded1987
Size (employees)3 (est)
Websiteimmudyne.com
Immudyne was founded in 1987 and is headquartered in Mount Kisco, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Immudyne

Justin Schreiber

Justin Schreiber

President & CEO

Immudyne Office Locations

Immudyne has an office in Mount Kisco
Mount Kisco, US (HQ)
50 Spring Meadow Rd
Show all (1)
Report incorrect company information

Immudyne Financials and Metrics

Immudyne Revenue

Immudyne's revenue was reported to be $5.24 m in FY, 2016 which is a 329.8% increase from the previous period.
USD

Revenue (Q2, 2018)

3.6 m

Gross profit (Q2, 2018)

2.8 m

Gross profit margin (Q2, 2018), %

75.6%

Net income (Q2, 2018)

(8.6 k)

EBIT (Q2, 2018)

(876.8 k)

Cash (30-Jun-2018)

691.2 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

808.4 k714.2 k1.2 m5.2 m

Revenue growth, %

(12%)71%330%

Cost of goods sold

181.3 k172.9 k247.8 k1.9 m

Gross profit

627.1 k541.3 k971.1 k3.3 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

277.4 k279.9 k1.6 m1.2 m1.4 m424.5 k1.6 m3.6 m

Cost of goods sold

89.5 k74 k1.3 m701 k942.7 k203.4 k355.5 k890.2 k

Gross profit

187.9 k205.9 k303.1 k526.3 k441.7 k221.1 k1.3 m2.8 m

Gross profit Margin, %

68%74%18%43%32%52%78%76%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

155.1 k75.5 k233 k182.6 k

Accounts Receivable

77.5 k15 k444.7 k

Inventories

86.2 k41 k61.1 k160.3 k

Current Assets

450.7 k131.5 k448.5 k789.8 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

61.1 k90 k70.1 k79.5 k73.9 k203.6 k235.5 k473.9 k381.1 k229.8 k691.2 k

Accounts Receivable

299.3 k451.1 k474.9 k555.7 k85.8 k64 k

Inventories

83.5 k54.9 k43.5 k21.5 k39.4 k138.5 k179.3 k130.5 k136.9 k601.2 k507.2 k

Current Assets

229.9 k255.5 k187 k236.4 k245 k641.5 k865.8 k1.1 m1.1 m1.3 m1.2 m1.5 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Depreciation and Amortization

57 k57 k43.7 k

Inventories

(22.8 k)45.2 k(20 k)(99.2 k)

Accounts Payable

(1.7 k)89 k(22 k)585.4 k

Cash From Operating Activities

33.4 k(295.1 k)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

8.1 k(108.2 k)(217.7 k)(651.9 k)640 k(8.6 k)

Depreciation and Amortization

28.5 k43.7 k10.5 k

Inventories

19.5 k1.6 k(77.4 k)(118.2 k)(69.5 k)23.3 k80.1 k174 k

Accounts Payable

39.9 k1.1 k169.5 k254.2 k240.7 k(188.5 k)(73.4 k)(29.5 k)
Show all financial metrics
Report incorrect company information

Immudyne Company Life and Culture

Report incorrect company information